Previous 10 | Next 10 |
Initiated dose expansion portion of UPGRADE-A clinical trial of UpRi in combination with carboplatin; interim data expected in second half of 2023 Advanced enrollment in Phase 3 UP-NEXT clinical trial of UpRi and Phase 1 clinical trial of XMT-1660 Plan to report topline data from ...
2023-05-08 13:14:01 ET Mersana Therapeutics ( NASDAQ: MRSN ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.48 (+18.6% Y/Y) and the consensus Revenue Estimate is $18.29M (+801.0% Y/Y). Over the la...
2023-05-03 13:05:45 ET Gainers: ImmunoGen ( IMGN ) +124% . GD Culture Group Limited ( GDC ) +115% . Aptorum Group Limited ( APM ) +92% . Aceragen ( ACGN ) +77% . NantHealth ( NH ) +57% . Sentage Holdings ( SNTG ) +61% ...
2023-05-03 10:01:41 ET Gainers: Aptorum ( APM ) +133% . ImmunoGen ( IMGN ) +123% . Akanda ( AKAN ) +63% . Mersana Therapeutics ( MRSN ) +37% . CNS Pharmaceuticals ( CNSP ) +25% . Losers: Assure ( IONM ) -38% ....
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the...
2023-04-03 17:20:34 ET Summary Concerns related to safety risks around ILD/pneumonitis are overblown in a disease of high unmet needs. I believe clinical benefits outweigh potential safety overhang, and key studies have put in the necessary steps to mitigate ILD risks. '1660 c...
2023-03-16 07:58:14 ET Mersana Therapeutics ( NASDAQ: MRSN ) added ~8% pre-market Thursday after JPMorgan upgraded the clinical-stage biotech ahead of a pivotal readout for its lead asset UpRi in ovarian cancer. The company is advancing the antibody-drug conjugate in a...
2023-03-13 08:40:34 ET Mersana Therapeutics, a biotech focused on antibody-drug conjugates (ADC) fell ~14% Monday in the pre-market trading after announcing that the FDA has placed a clinical hold on its Phase 1 trial for cancer candidate XMT-2056. The decision comes after inv...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...